TCGA-64-5779-01A-01R-1628-07
— · cohortA3
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA3
- subtype
- cohortA3
- age_years
- 61
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANGIOGENESIS+0.300
- SPERMATOGENESIS+0.260
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.250
- TGF_BETA_SIGNALING+0.150
- PANCREAS_BETA_CELLS+0.140
- NOTCH_SIGNALING+0.130
- MYOGENESIS+0.120
- HEDGEHOG_SIGNALING+0.110
- KRAS_SIGNALING_UP+0.110
- UV_RESPONSE_DN+0.100
Top 10 suppressed
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.530
- INTERFERON_ALPHA_RESPONSE-0.430
- FATTY_ACID_METABOLISM-0.400
- OXIDATIVE_PHOSPHORYLATION-0.380
- ADIPOGENESIS-0.370
- MTORC1_SIGNALING-0.370
- P53_PATHWAY-0.370
- MYC_TARGETS_V2-0.360
- GLYCOLYSIS-0.350
- MYC_TARGETS_V1-0.340
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | ba2b0b86-f7f1-47f7-b0fd-bec3f623febb | — | — | 0.859 |
| 2 | fe036511-fe82-467c-9c6e-59bfb8b0a329 | — | — | 0.851 |
| 3 | TCGA-WA-A7H4-01A-21R-A34R-07 | — | — | 0.848 |
| 4 | SRR10899993 | — | — | 0.835 |
| 5 | TCGA-CQ-7072-01A-21R-A30B-07 | — | — | 0.831 |
| 6 | s0122214 | — | — | 0.826 |
| 7 | TCGA-CN-A49A-01A-11R-A24H-07 | — | — | 0.825 |
| 8 | TCGA-A7-A13D-01B-04R-A277-07 | — | D | 0.824 |
| 9 | 824433bf-151c-46ea-9ea7-f53813f66a97 | — | — | 0.824 |
| 10 | 69550f7f-5251-4657-863b-bd35d69c82c4 | — | — | 0.817 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANGIOGENESIS | 0.300 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.260 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.250 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.150 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.140 | Cobimetinib | — uncovered |
| NOTCH_SIGNALING | 0.130 | Inavolisib | — uncovered |
| MYOGENESIS | 0.120 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.110 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.110 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.100 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.070 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.030 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.030 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.020 | Inavolisib | — uncovered |